Valbenazine is an active pharmaceutical ingredient used in medicines targeting movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. The API landscape is shaped by pharmaceutical quality requirements, controlled manufacturing processes, regulatory oversight, supply continuity, and the need to support consistent finished-dose production. Strategic assessment should therefore focus on development status, manufacturing readiness, quality systems, intellectual-property considerations, and the regulatory pathways relevant to each intended product.

Regulatory and Manufacturing Shifts Reshaping Valbenazine API Supply

The landscape is moving toward tighter integration between API development, analytical characterization, process validation, and finished-product regulatory submissions. Manufacturers and buyers are placing greater emphasis on impurity control, robust specifications, documentation packages, inspection readiness, and reliable sourcing of specialized intermediates. Additional priorities include secure supply chains, dual-source planning where feasible, environmental controls, and manufacturing flexibility that can support changes in formulation, dosage strength, or regional registration requirements.

How Artificial Intelligence Is Changing API Development and Operations

Artificial intelligence can support valbenazine API activities by accelerating literature and patent review, identifying process-development variables, monitoring analytical data, and detecting potential deviations in manufacturing operations. Machine-learning tools may also assist demand planning, supplier-risk screening, batch-record review, and preventive-maintenance programs. These applications require validated data, human oversight, explainable decision criteria, and compliance with applicable computerized-system and pharmaceutical quality expectations; AI should augment rather than replace qualified process, quality, and regulatory experts.

Regional Insights Across the Global Valbenazine API Landscape

North America is influenced by established regulatory expectations, specialty-pharmaceutical development capabilities, and demand for dependable API documentation. Latin America presents opportunities linked to expanding pharmaceutical access while requiring careful attention to registration procedures, import controls, and local procurement practices. Europe emphasizes stringent quality, environmental, and supply-chain requirements across the European regulatory framework. The Middle East is shaped by centralized procurement in some markets and reliance on compliant international suppliers. Africa requires adaptable distribution and regulatory strategies that reflect varied national capacities. Asia-Pacific combines strong pharmaceutical manufacturing capabilities with diverse approval systems, cost pressures, and growing interest in supply-chain resilience.

Group-Level Priorities Across ASEAN, BRICS, EU, G7, GCC, and NATO Markets

ASEAN markets require coordinated attention to differing national registration rules, import requirements, and manufacturing capabilities. BRICS economies combine substantial pharmaceutical demand with varied regulatory maturity, domestic-production policies, and sourcing preferences. The European Union places particular weight on harmonized quality expectations, qualified-person oversight, and environmental compliance. G7 markets generally demand extensive technical documentation, traceability, and inspection readiness. GCC countries often emphasize reliable imported supply, centralized purchasing, and national registration requirements. NATO members are not governed by a single pharmaceutical market framework, but many prioritize resilient medical supply chains, regulatory compliance, and continuity planning.

Country-Level Considerations for Valbenazine API Strategy

Australia and Canada require alignment with national therapeutic-goods authorities and import documentation. Brazil and Mexico call for careful navigation of local registration, localization, and procurement requirements. China and India combine significant pharmaceutical manufacturing capacity with detailed domestic regulatory procedures and evolving quality expectations. Japan and South Korea emphasize rigorous product quality, documentation, and local regulatory engagement. France, Germany, Italy, Spain, and the United Kingdom require strong compliance with European or national pharmaceutical frameworks, with particular attention to quality systems and supply continuity. Russia presents a distinct regulatory and logistics environment requiring country-specific assessment. The United States remains a highly regulated setting in which API suppliers must support comprehensive quality, manufacturing, and regulatory documentation.

Strategic Actions for Valbenazine API Industry Leaders

Industry leaders should establish a risk-based API strategy covering process robustness, impurity profiles, analytical-method validation, supplier qualification, and change control. They should maintain complete technical documentation for regulatory submissions, conduct routine quality audits, and evaluate contingency plans for critical raw materials and manufacturing sites. Regional launch planning should map registration requirements before commercial commitments are made. Investment in digital batch review, supply-chain visibility, and carefully governed AI tools can improve responsiveness, but implementation should remain anchored in data integrity, cybersecurity, validation, and accountability. Partnerships should be assessed on demonstrated compliance and manufacturing reliability rather than price alone.

Research Methodology for the Valbenazine API Executive Summary

This summary uses a structured qualitative framework focused on the characteristics of the valbenazine API supply and regulatory environment. The assessment considers therapeutic relevance, manufacturing and quality requirements, regulatory variation, regional operating conditions, group-level policy and procurement context, country-level market access considerations, supply-chain resilience, and the potential role of artificial intelligence. No market estimates, market shares, forecasts, or company-specific claims are used. Conclusions should be validated against current regulatory filings, official guidance, inspection records, scientific literature, patent information, and directly verified supplier documentation before investment or sourcing decisions.

Conclusion: Building a Compliant and Resilient Valbenazine API Platform

The valbenazine API landscape rewards disciplined execution across chemistry, manufacturing, quality, regulatory affairs, and supply-chain management. Success depends on consistent API quality, defensible documentation, region-specific compliance planning, and resilience against raw-material, logistics, and operational disruptions. Organizations that combine robust technical controls with transparent supplier governance and responsible digital adoption will be better positioned to support reliable finished-product development and registration across diverse international markets.

Product Code: MRR-961F26FD648A

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Valbenazine API Market, by Dosage Strength

7.1. Introduction
7.2. 40 Mg
7.3. 80 Mg

8. Valbenazine API Market, by Treatment Setting

8.1. Introduction
8.2. Inpatient
8.3. Outpatient

9. Valbenazine API Market, by Patient Age Group

9.1. Introduction
9.2. Adults 18 To 64
- 9.2.1. 18 To 40
- 9.2.2. 41 To 64
9.3. Elderly 65 Plus

10. Valbenazine API Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacy
10.3. Retail Pharmacy
10.4. Specialty Pharmacy

11. Valbenazine API Market, by Region

11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa

12. Valbenazine API Market, by Group

12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO

13. Valbenazine API Market, by Country

13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea

14. Competitive Landscape

14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
- 14.2.1. Concentration Ratio (CR)
- 14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025

15. Company Profiles

15.1. Acharya Chemicals
15.2. Apotex Pharmachem
15.3. Crystal Pharmaceutical
15.4. F.I.S. Fabbrica Italiana Sintetici
15.5. Farmhispania
15.6. Globe Quimica Ltda
15.7. Jubilant Generics
15.8. Lupin Manufacturing Solutions
15.9. Mitsubishi Tanabe Pharma
15.10. MSN Laboratories
15.11. MSN Life Sciences Private Ltd
15.12. Synthimed Labs
15.13. TAPI Technology & API Services
15.14. Teva Pharmaceutical Industries
15.15. Viatris

16. Key Experts

Product Code: MRR-961F26FD648A

LIST OF FIGURES

FIGURE 1. Global Valbenazine API Market, Years Considered for the Study
FIGURE 2. Global Valbenazine API Market, Research Design
FIGURE 3. Global Valbenazine API Market, Research Framework
FIGURE 4. Global Valbenazine API Market, Data Triangulation
FIGURE 5. Global Valbenazine API Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Valbenazine API Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 7. Global Valbenazine API Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Valbenazine API Market Size, by Treatment Setting, 2025 vs 2032 (%)
FIGURE 9. Global Valbenazine API Market Size, by Treatment Setting, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Valbenazine API Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 11. Global Valbenazine API Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Valbenazine API Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Valbenazine API Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Valbenazine API Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Valbenazine API Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Valbenazine API Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Valbenazine API Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Valbenazine API Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Valbenazine API Market Share, by Key Player, 2025

LIST OF TABLES

TABLE 1. Global Valbenazine API Market Segmentation & Coverage
TABLE 2. Global Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 3. Global Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 4. Global 40 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global 40 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global 40 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global 80 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global 80 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global 80 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 11. Global Inpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Inpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Inpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Outpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Outpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Outpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 18. Global Adults 18 To 64 Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Adults 18 To 64 Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Adults 18 To 64 Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global 18 To 40 Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global 18 To 40 Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global 18 To 40 Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global 41 To 64 Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global 41 To 64 Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global 41 To 64 Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Elderly 65 Plus Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Elderly 65 Plus Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Elderly 65 Plus Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 31. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Asia-Pacific Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Asia-Pacific Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 43. Asia-Pacific Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 44. Asia-Pacific Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 45. Asia-Pacific Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 46. Asia-Pacific Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 47. North America Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. North America Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 49. North America Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 50. North America Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 51. North America Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 52. North America Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 53. Latin America Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Latin America Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 55. Latin America Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 56. Latin America Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 57. Latin America Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 58. Latin America Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 59. Europe Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Europe Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 61. Europe Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 62. Europe Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 63. Europe Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 64. Europe Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 65. Middle East Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Middle East Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 67. Middle East Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 68. Middle East Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 69. Middle East Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 70. Middle East Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 71. Africa Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Africa Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 73. Africa Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 74. Africa Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 75. Africa Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 76. Africa Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Global Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. ASEAN Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. ASEAN Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 80. ASEAN Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 81. ASEAN Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 82. ASEAN Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 83. ASEAN Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. GCC Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. GCC Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 86. GCC Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 87. GCC Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 88. GCC Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 89. GCC Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. European Union Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. European Union Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 92. European Union Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 93. European Union Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 94. European Union Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 95. European Union Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. BRICS Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. BRICS Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 98. BRICS Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 99. BRICS Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 100. BRICS Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 101. BRICS Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. G7 Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. G7 Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 104. G7 Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 105. G7 Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 106. G7 Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 107. G7 Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 108. NATO Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. NATO Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 110. NATO Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 111. NATO Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 112. NATO Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 113. NATO Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. Global Valbenazine API Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. United States Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 116. United States Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 117. United States Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 118. United States Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 119. United States Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 120. United States Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. Canada Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 122. Canada Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 123. Canada Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 124. Canada Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 125. Canada Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 126. Canada Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. Mexico Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 128. Mexico Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 129. Mexico Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 130. Mexico Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 131. Mexico Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 132. Mexico Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 133. Brazil Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 134. Brazil Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 135. Brazil Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 136. Brazil Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 137. Brazil Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 138. Brazil Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. United Kingdom Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 140. United Kingdom Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 141. United Kingdom Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 142. United Kingdom Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 143. United Kingdom Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 144. United Kingdom Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. Germany Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 146. Germany Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 147. Germany Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 148. Germany Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 149. Germany Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 150. Germany Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. France Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 152. France Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 153. France Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 154. France Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 155. France Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 156. France Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. Russia Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 158. Russia Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 159. Russia Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 160. Russia Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 161. Russia Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 162. Russia Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. Italy Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 164. Italy Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 165. Italy Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 166. Italy Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 167. Italy Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 168. Italy Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. Spain Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 170. Spain Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 171. Spain Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 172. Spain Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 173. Spain Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 174. Spain Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. China Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 176. China Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 177. China Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 178. China Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 179. China Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 180. China Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. India Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 182. India Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 183. India Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 184. India Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 185. India Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 186. India Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. Japan Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 188. Japan Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 189. Japan Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 190. Japan Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 191. Japan Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 192. Japan Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 193. Australia Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 194. Australia Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 195. Australia Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 196. Australia Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 197. Australia Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 198. Australia Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. South Korea Valbenazine API Market Size, 2017-2032 (USD Million)
TABLE 200. South Korea Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 201. South Korea Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 202. South Korea Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 203. South Korea Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
TABLE 204. South Korea Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Global Valbenazine API Market Share, by Key Player, 2025
TABLE 206. Global Valbenazine API Market, Key Experts

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION